Research Updates

Stem Cell Model of Familial Alzheimer's Identifies New AD Genes

Posted: Jan. 8, 2014

A stem cell model of familial Alzheimer’s disease (FAD) was successfully generated in a recent study, allowing researchers to identify 14 genes potentially implicated in the disease. One gene in particular demonstrates the important role inflammation may play in the brain of Alzheimer’s patients. The study was completed by scientists at The New York Stem Cell Foundation (NYSCF) Research Institute in collaboration with scientists at the Icahn School of Medicine at Mount Sinai (ISMMS) and funded in part by the Cure Alzheimer’s Fund (CAF).

Living Brain Cells Created from Biobanked Alzheimer's Brain Tissue

Posted: Jan. 8, 2014

Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute, working in collaboration with scientists from Columbia University Medical Center (CUMC), for the first time generated induced pluripotent stem (iPS) cells lines from non-cryoprotected brain tissue of patients with Alzheimer’s disease.

Circadian Clock Proteins a Potential Therapeutic Target for Alzheimer’s

Posted: Dec. 19, 2013

Brain aging is associated with lower production of circadian clock proteins, which synchronize biological processes to light and dark cycles. In Alzheimer’s and other neurodegenerative diseases, circadian dysfunction is commonly observed.

New Tanzi Paper Identifies Two Late-Onset Gene Mutations

Posted: Sep. 20, 2013

In a paper just published in the prestigious journal Neuron, Harvard Medical School/Mass General Hospital Geneticist Dr. Rudy Tanzi, together with lead author, Dr. Jaehong Suh and their team, identified two rare mutations in the human gene called "ADAM10" that lead to the most common, late-onset variant of Alzheimer's. Tanzi's research suggests that the ADAM10 gene makes an enzyme called alpha-secretase, which cleaves the Amyloid Precursor Protein (APP) to prevent the formation of beta-amyloid, the toxic protein that triggers brain pathology in Alzheimer's disease.

Cholesterol and Alzheimer's: A Big Step Forward

Posted: Jul. 29, 2013

For several years now, researchers have been aware of important links between cholesterol and Alzheimer's disease. A new study by Dr. Dora Kovacs and her team at Massachusetts General Hospital brings us one step closer to a potential drug that could interrupt the disease process.

Public/Private Effort Yields Key Progress

Posted: Jul. 18, 2013

An innovative new public/private collaboration between Cure Alzheimer’s Fund and the National Institute of Mental Health (NIMH) already has started to bear fruit.

Alzheimer's Proteins Found In Cerebrospinal Fluid of Older Patients Post Surgery

Posted: Jul. 1, 2013

BOSTON – New research examining levels of the hallmark proteins linked to Alzheimer's disease found in patients suffering from post-operative cognitive changes (POCC) may lead to safer surgery care and better post-operative outcomes for senior adults.

Newly Identified Gene Variations Provide Clues About Origins of Alzheimer’s

Posted: Jun. 18, 2013

Research uncovering 12 new gene variations connected to the cause of the early-onset familial form of Alzheimer’s disease (EO-FAD), which generally strikes before the age of 65, is being published in the journal Molecular Psychiatry.

Targretin Fails: High Hopes Dashed for a New Treatment for Alzheimer’s

Posted: May 24, 2013

While many were anxious to accept initial findings showing a drug known as Targretin’s “too good to be true” lab results with Alzheimer’s disease, subsequent attempts to confirm and replicate the original data regarding the ability of Targretin to remove amyloid plaques, the cardinal lesion of the disease, have largely failed. Cure Alzheimer’s Fund Research Consortium members Dr. Sangram Sisodia, professor of neuroscience at the University of Chicago and Dr.

New Alzheimer’s Gene, CD33, May Hold Key to Treatment

Posted: Apr. 25, 2013

BOSTON— Excessive levels of the protein CD33 can impede the clearance of the plaque-forming protein, amyloid beta, the key component of senile plaques in the brains of Alzheimer’s disease patients. The discovery, made by Dr. Rudolph Tanzi and colleagues at Massachusetts General Hospital, and co-funded by the Cure Alzheimer’s Fund and the National Institute of Mental Health (NIMH) will be published in the journal Neuron.